



EU Risk Management Plan for Ebglyss 250 mg solution for injection (Lebrikizumab)

RMP Version number:	1.3
Data lock point for this RMP:	23 Feb 2026
Date of final sign off:	26 Feb 2026
Rationale for submitting an updated RMP:	To update the submission date of the final CSR for the M-17923-32 study.
Summary of significant changes in this RMP:	Submission date for CSR of M-17923-32 study updated in Part 3 - Section III.3 Summary Table of Additional Pharmacovigilance Activities and Annex 2 – table II.1 Planned and ongoing studies. Postmarketing exposure data was updated.
Other RMP versions under evaluation:	Not applicable
Details of the currently approved RMP:	
Version number:	1.2
Approved with procedure:	EMA/VR/0000249804
Date of approval (opinion date):	02/Oct/2025

QPPV name:

Delia Cristiana Canulescu

[REDACTED]

[REDACTED]

Table of Contents

Section	Page
Table of Contents	3
List of Tables	5
List of Abbreviations	6
Part I: Product(s) Overview	7
Part II: Safety Specification	9
Module SI - Epidemiology of the Indication(s) and Target Population(s).....	9
SI.1 Atopic Dermatitis	9
Module SII – Non-clinical Part of the Safety Specification.....	18
Key safety findings from non-clinical studies and relevance to human usage:	18
SII.1 Toxicity	18
SII.2 Safety Pharmacology	18
SII.3 Other Toxicity-Related Information or Data	18
Module SIII - Clinical Trial Exposure.....	19
Module SIV - Populations Not Studied in Clinical Trials.....	25
SIV.1 Exclusion Criteria in Pivotal Clinical Studies within the Development Programme	25
SIV.2 Limitations to Detect Adverse Reactions in Clinical Trial Development Programmes	25
SIV.3 Limitations in Respect to Populations Typically Under-Represented in Clinical Trial Development Programmes	26
Module SV - Post-Authorisation Experience	27
SV.1 Post-Authorisation Exposure	27
Module SVI – Additional EU requirements for the Safety Specification	28
SVI.1 - Potential for Misuse for Illegal Purposes	28
Module SVII - Identified and Potential Risks	29
SVII.1 Identification of Safety Concerns in the Initial RMP Submission.....	29
SVII.2 New Safety Concerns and Reclassification with a Submission of an Updated RMP.....	32
SVII.3 Details of Important Identified Risks, Important Potential Risks, and Missing Information.....	32
Module SVIII - Summary of the Safety Concerns	34
Part III: Pharmacovigilance Plan (Including Post-Authorisation Safety Studies)	35
III.1 Routine Pharmacovigilance Activities.....	35

III.2 Additional Pharmacovigilance Activities	35
III.3 Summary Table of Additional Pharmacovigilance Activities	38
Part IV: Plans for Post-Authorisation Efficacy Studies.....	41
Part V: Risk Minimisation Measures (Including Evaluation of the Effectiveness of Risk Minimisation Activities).....	42
V.1 Routine Risk Minimisation Measures.....	42
V.2 Additional Risk Minimisation Measures	42
V.3 Summary of Risk Minimisation Measures.....	43
Part VI: Summary of the risk management plan for Ebglyss (Lebrikizumab)	44
I. The medicine and what it is used for	44
II. Risks associated with the medicine and activities to minimise or further characterise the risks.....	44
II.A List of important risks and missing information.....	45
II.B Summary of important risks.....	45
II.C Post-authorisation development plan	46
II.C.1 Studies which are conditions of the marketing authorisation.....	46
II.C.2 Other studies in post-authorisation development plan	47
Part VII: Annexes	48
Annex 4. Specific adverse drug reaction follow-up forms	55
Annex 6. Details of Proposed Additional Risk Minimisation Activities (if applicable)	57

List of Tables

Table		Page
Table Part I.1.	Product Overview	7
Table SI.1.	Prevalence of Atopic Dermatitis	9
Table SI.2.	Important Co-morbidities.....	13
Table SIII.1.	Duration of Lebrikizumab Exposure	19
Table SIII.2.	Age Group and Gender	20
Table SIII.3.	Dose	21
Table SIII.4.	Ethnic Origin.....	22
Table SIII. 5.	Estimated Cumulative Subject Exposure in Completed and Ongoing Lebrikizumab Clinical Trials as of 16 November 2024.....	22
Table SIII. 6.	Cumulative Subject Exposure to Lebrikizumab by Age Group and Gender: All Completed and Unblinded Ongoing Clinical Trials through 16 November 2024	23
Table SIII. 7.	Exposure by Treatment Group Study KGAA Main Cohort Modified Safety Population	23
Table SIII. 8.	Exposure by Treatment Group Study KGBQ Safety Population.....	24
Table SIV.1.	Exposure of Special Populations Included or Not in Clinical Trial Development Programmes.....	26
Table SV.1.	Cumulative Geographical Summary Estimated Patient Exposure for lebrikizumab through 31 October 2024	27
Table SVII.1.	Neonate Birth Type in Lebrikizumab Clinical Trials by Indication	33
Table SVIII.1.	Summary of Safety Concerns	34
Table Part III.1.	Ongoing and Planned Additional Pharmacovigilance Activities.....	38
Table Part V.1.	Description of Routine Risk Minimisation Measures by Safety Concern	42
Table Part V.3.	Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern.....	43
Table Annex II.1.	Planned and Ongoing Studies	50
Table Annex II.2.	Completed Studies	53

List of Abbreviations

Term	Definition
AD	atopic dermatitis
AD ALL LEB	Atopic Dermatitis All Lebrikizumab Exposure Analysis Set
AD ALL PC Weeks 0 to 16	Atopic Dermatitis Induction Period Placebo-Controlled Integrated Analysis Set
AE	Adverse event
CI	confidence interval
COPD	chronic obstructive pulmonary disease
EDD	Estimated Daily Dose
HR	hazard ratio
IPF	idiopathic pulmonary fibrosis
ISR	injection-site reactions
JAK	Janus kinase
MACE	major adverse cardiovascular event
Mg	milligrams
NMSC	non-melanoma skin cancer
OR	odds ratio
PL	Package leaflet
PY	patient-years
Q2W	every 2 weeks
Q4W	every 4 weeks
RHL	refractory Hodgkin's lymphoma
RMP	risk management plan
SAE	Serious adverse event
SmPC	Summary of product characteristics
TCS	topical corticosteroids
TCI	Topical calcineurin inhibitors
TEAE	treatment emergent adverse event
UK	United Kingdom
US	United States

Part I: Product(s) Overview

Table Part I.1. Product Overview

Active substance(s) (INN or common name)	Lebrikizumab
Pharmacotherapeutic group(s) (ATC Code)	D11AH10
Marketing Authorisation <Holder> <Applicant>	Almirall S.A.
Medicinal products to which this RMP refers	1
Invented name(s) in the European Economic Area (EEA)	Ebglyss 250 mg solution for injection in pre-filled syringe Ebglyss 250 mg solution for injection in pre-filled pen
Marketing authorisation procedure	Centralised
Brief description of the product	Chemical class: Lebrikizumab is a recombinant antibody produced in Chinese hamster ovary cells. It consists of 2 heavy chains (445 amino acid residues each) and 2 light chains (218 amino acid residues each) with inter- and intra-chain disulfide bonds that are typical of IgG4 antibodies. Summary of mode of action Lebrikizumab is an IgG4 mAb that binds with high affinity and slow off-rate to IL-13 and selectively inhibits IL-13 signalling through the IL-4 receptor alpha/IL-13 receptor alpha 1 pathway, thereby blocking the downstream effects of IL-13 with high potency. Lebrikizumab-bound IL-13 can still bind IL-13 receptor alpha 2 allowing subsequent internalisation and natural clearance of IL-13. Blockade of IL-13 signalling is expected to be of benefit in diseases where IL-13 is a central cytokine to the disease pathogenesis, such as AD. Important information about its composition: Lebrikizumab is a mAb based on the human IgG4 stabilised by a mutated Fc region.
Hyperlink to the Product Information	13-pi
Indication(s) in the EEA	Current: Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
Dosage in the EEA	Current dosage for adult and adolescent patients: The recommended dose of Ebglyss is 500 mg (two 250 mg injections) at both week 0 and week 2, followed by 250 mg administered subcutaneously every other week up to week 16. Consideration should be given to discontinuing treatment in patients who have shown no clinical response after 16 weeks of treatment. Some patients with initial partial response may further improve with continued treatment every other week up to week 24.

	Once clinical response is achieved, the recommended maintenance dose of Ebglyss is 250 mg every fourth week.
Pharmaceutical form(s) and strengths	Current: Lebrikizumab is supplied as a sterile, liquid formulation for subcutaneous (SC) use. Lebrikizumab is supplied as a 2-mL pre-filled syringe with needle safety device (PFS-NSD) and as a pre-filled pen. The SC formulation contains 125 mg/mL lebrikizumab, L-histidine (3.1 mg/mL), acetic acid, glacial (0.9 mg/mL), sucrose (59.8 mg/mL), polysorbate 20 (0.3 mg/mL), and water for injection, pH 5.4 to 6.0.
Is/will the product be subject to additional monitoring in the EU?	Yes

Abbreviations: AD = atopic dermatitis; ATC = Anatomical Therapeutic Chemical; Fc = fraction crystallisable; IgG4 = immunoglobulin G4; IL = interleukin; INN = International Non-proprietary Names; mAb = monoclonal antibody.

Part II: Safety Specification

Module SI - Epidemiology of the Indication(s) and Target Population(s)

SI.1 Atopic Dermatitis

SI.1.1 Incidence

Worldwide, the incidence of AD is not well documented. The only identified study reported an incidence of 6.1 per 1000 PY during 2002 to 2006 in the Netherlands (6.5 versus 5.7 for males versus females, respectively) ([Verhoeven et al. 2008](#)). The incidence rates for AD in Danish (born from 1997 to 2011) and Swedish (born from 2006 to 2010) children were 21.5 and 30.6 per 1000 PY, respectively ([Henriksen et al. 2015](#)).

SI.1.2 Prevalence

The 1-year prevalence of AD among adults is estimated between 2% to 8% in the US, Europe, and Japan ([Saeki et al. 2006](#); [Harrop et al. 2007](#); [Diepgen et al. 2016](#); [Barbarot et al. 2018](#); [Sacotte and Silverberg 2018](#)). Approximately 30% of adult patients with AD have moderate-to-severe disease ([Bieber and Straeter 2015](#)). Table SI.1. presents the prevalence of AD among adults in various countries ([Barbarot et al. 2018](#)).

Table SI.1. Prevalence of Atopic Dermatitis

Country/Region	12-month prevalence (%) of AD (with 95% CI) (Barbarot et al. 2018)
US	4.9 (4.6 to 5.2)
Canada	3.5 (3.1 to 3.9)
Japan	2.1 (1.8 to 2.3)
EU	4.4 (4.2 to 4.6)
France	3.6 (3.2 to 4.0)
Germany	2.2 (1.9 to 2.5)
Italy	8.1 (7.5 to 8.6)
Spain	7.2 (6.7 to 7.7)
UK	2.5 (2.2 to 2.8)

Abbreviations: AD = atopic dermatitis; CI = confidence interval.

The 1-year prevalence among individuals aged 12 to 18 years was estimated to be 14.8% based on a multinational, cross-sectional survey study ([Silverberg et al. 2021](#)). Within this survey, less than 15% patients with AD reported severe AD. In a survey of 663 256 participants aged 13 to 14 years from 96 countries ([Odhiambo et al. 2009](#)), the prevalence ranged from 0.2% (Tibet, China) to 24.6% (Barranquilla, Colombia) for current eczema symptoms, and 0% to 5.8% (Marrakech, Morocco) for symptoms of severe eczema.

SI.1.3 Demographics of the Population in the Indication and Risk Factors for the Disease

Gender

Multiple studies have shown a higher prevalence of AD among females compared with males. For example, in a multinational survey within 8 countries, females had a higher prevalence than males in Canada (4.0% versus 3.0%), France (4.5% versus 2.6%), Germany (2.6% versus 1.8%), Italy (10.0% versus 6.0%), and Spain (9.3% versus 6.1%); whereas the UK, the US, and Japan reported similar prevalence of AD between men and women ([Barbarot et al. 2018](#)). Despite this finding of similar prevalence among Japanese population in the survey study by Barbarot et al., a different clinic-based study in Japan did find a higher prevalence of AD among women (9.3%) compared with men (5.1%) ([Saeki et al. 2006](#)). Additionally, 2 large population-based studies of patients with AD in Denmark reported that a higher proportion of patients with AD were female (61.8%) compared to male (38.2%) ([Vinding et al. 2014](#); [Egeberg et al. 2017a](#)).

Age

The prevalence of AD among adults is well-recognized to be lower than that of children, with AD reported in 15% to 20% of children ([Nutten 2015](#)). Even within an adult population, the prevalence of AD decreases with increasing age ([Saeki et al. 2006](#); [Wolkewitz et al. 2007](#); [Vinding et al. 2014](#)). For example, in a German study, the prevalence of AD was 5.3%, 3.9%, and 3.4% in adults aged 50 to 59, 60 to 69, and 70 to 74 years, respectively ([Wolkewitz et al. 2007](#)).

Race/Ethnicity

There is a paucity of data describing the prevalence of AD in skin of colour populations. As reported by [Silverberg and Hanifin 2013](#), in 1 survey study within the US that asked “During the past 12 months, have you had dermatitis, eczema, or any other red, inflamed skin rash?”, the prevalence was

- 7.7% among African American participants
- 10.5% in White participants
- 9.1% in Asian participants, and
- 14.6% in participants reporting “other/multiracial”.

One US-based study reported no increased odds of AD among participants who were Black or Hispanic, compared with non-Hispanic White; however, those who were Multiracial, non-Hispanic had increased odds of AD (OR 3.36, 95% CI: 1.31 to 8.58) when compared with non-Hispanic Whites ([Chiesa et al. 2019](#)).

Risk factors

Risk factors for the development of AD include a family history of AD as well as family and personal history for other atopic diseases, including asthma, allergic rhinitis, food allergies, and hay fever. Genetic risk factors have been suggested, particularly mutations in the filaggrin gene

(Weidinger and Novak 2016). Environmental risk factors for development of AD include Western diets that are high in sugar and poly-unsaturated fatty acids, small family size, high education, and living in urban settings with low exposure to ultraviolet radiation and low humidity (Weidinger and Novak 2016). The presence of multiple comorbid autoimmune diseases shows an increased association with AD. The ORs for those with AD who have 1, 2, and at least 3 autoimmune diseases, are 2.48 (95% CI: 2.26 to 2.71), 3.46 (95% CI: 2.58 to 4.64), and 5.32 (95% CI: 1.87 to 15.18), respectively ([Andersen et al. 2017](#)).

SI.1.4 Main Existing Treatment Options

Pharmacologic therapies

Topical corticosteroids

TCS are typically the first-line treatment for moderate-to-severe AD and are effective as a short-term treatment or intermittent long-term treatment. However, continuous long-term use of TCS is not recommended because of the risk of local and systemic side effects (skin atrophy, dyspigmentation, and hypertension).

Topical calcineurin inhibitors

TCIs are considered as an alternative or adjunct treatment, especially where treatment with TCS is either inadvisable or not possible and for steroid-sparing in sensitive areas, such as face and skin folds.

As with TCS, TCI are effective as continuous short-term treatments or intermittent long-term treatment. However, patients with moderate-to-severe AD often need additional therapies to alleviate their most bothersome symptoms.

Topical JAK inhibitor

Ruxolitinib is the first JAK inhibitor approved in the US as topical cream for treatment of mild to moderate AD in patients aged 12 years and older. Ruxolitinib cream is indicated for short-term and non-continuous chronic treatment ([Opzelura package insert, 2022](#)). Therefore, alternative therapeutic options are needed for longer-term, continuous treatment to control chronic skin inflammation in patients with moderate-to-severe AD.

Systemic JAK inhibitors

Baricitinib is an oral small-molecule inhibitor of JAK1, approved in Europe since 2020 for the treatment of moderate-to-severe AD in adults who are candidates for systemic therapy.

Abrocitinib and upadacitinib were approved in 2021 for the treatment of moderate-to-severe AD in adults and adolescents (12 years and older) who are candidates for systemic therapy ([Deeks and Duggan 2021](#), [Traidl et al. 2021](#)). Abrocitinib is approved only for adults in the US. Additionally, in the US, the use of abrocitinib and upadacitinib is restricted to patients with refractory, moderate-to-severe AD whose disease is not adequately controlled with other systemic drug products, including biologics. Their use is also limited based on increased risk of serious bacterial, fungal,

viral, and opportunistic infections leading to hospitalisation or death mortality, malignancies, MACE, and thrombosis associated with the JAK inhibitor class ([Rinvoq package insert, 2022](#); [Cibinqo package insert, 2022](#)).

Other systemic immunosuppressive agents

Other systemic immunosuppressive agents are often used when topical treatment does not achieve sufficient control of AD symptoms. Currently available systemic therapies include non-selective immunosuppressants, such as cyclosporine A, azathioprine, methotrexate, and systemic corticosteroids. Among these, only cyclosporine is approved in some regions for treatment of moderate-to-severe AD and its use is limited to adult patients. Most guidelines recommend systemic corticosteroids only for short-term AD treatment due to severe toxicity and side effects.

Biologic agents

Anti-IL4/IL13 antibody

Dupilumab is an injectable anti-IL-4/IL-13 antibody that was approved as the first biologic for moderate-to-severe AD in 2017. Dupilumab is currently indicated in the US for the treatment of moderate-to-severe AD in adult and paediatric patients aged 6 months and older and in the EU for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older or severe atopic dermatitis in children 6 months to 11 years old.

Anti-IL13 antibody

Tralokinumab is an injectable anti-IL-13 antibody that was approved in 2021 for adult patients with moderate-to-severe AD.

Dupilumab and tralokinumab are effective treatments for some patients while others may show a limited or partial response or even no response at all to treatment. Some patients may show an initial response to treatment and lose response over time.

SI.1.5 Natural History of the Indicated Condition in the Population, Including Mortality and Morbidity

AD is a disease more commonly associated with infancy and childhood; however, it is prevalent among adults as well. Among adult patients with AD, approximately 80% are relapsing-remitting disease from childhood, whereas an estimated 20% are new onset in adulthood ([Akdis et al. 2006](#); [Garmhausen et al. 2013](#)). Approximately 30% of the patients with AD have moderate-to-severe disease ([Bieber and Straeter 2015](#)). The proportion of AD cases that are severe increases with age ([Silverberg and Simpson 2014](#)), resulting in moderate-to-severe AD being more prevalent among adult patients than children. For example, a Danish study on adult patients with AD found that 58.2% of the patients had severe disease ([Egeberg et al. 2017a](#)).

Depending on age of onset and disease course, atopy signs and concomitant atopic diseases may differ significantly ([Garmhausen et al. 2013](#)). Patients experience significant morbidity from moderate-to-severe AD including skin lesions, intractable pruritus, sleep disturbance, and skin

pain ([Weidinger and Novak 2016](#); [Vakharia et al. 2017](#)). The persistent itch-scratch cycle can have substantial impacts on physical, emotional, and quality of life measures ([Augustin et al. 2022](#)). A study of adults with moderate-to-severe AD found 21.8% of the patients had clinically relevant anxiety or depression. In severe AD, 100% of the patients had borderline and/or abnormal Hospital Anxiety and Depression Scale scores. Furthermore, patients with AD have an increased risk of bacterial and viral infections, both cutaneous and non-cutaneous, due to defective skin barrier and immunologic dysregulation ([Langan et al. 2017](#)). Approximately 70% of the patients with active AD have colonisation with *Staphylococcus aureus* ([Clausen et al. 2017](#)). The prevalence of methicillin-resistant *S. aureus* is significantly higher among patients with moderate-to-severe AD compared to those with mild AD (90% versus 10%) ([Ong and Leung 2016](#)). There is a significant association between moderate-to-severe AD and occurrence of depression, anxiety, and suicidal ideation ([Ronnstad et al. 2018](#); [Thyssen 2018a](#)).

AD is not a life-threatening condition and until recently, there had been no published research on the impact, if any, on mortality. However, some studies have shown that while the absolute risk of death is very low, there may be a modestly increased risk of death among adult patients with AD compared with a general population (HR = 1.71, 95% CI: 1.20 to 2.44 [[Egeberg et al. 2017b](#)] and HR = 1.27, 95% CI: 1.11 to 1.45 [[Thyssen et al. 2018b](#)]). The mortality rate among patients with AD was 0.579 per 100 PY (95% CI: 0.511 to 0.656) ([Thyssen et al. 2018b](#)).

SI.1.6 Important Co-morbidities

[Table SI](#) presents the co-morbidities that occur frequently in patients with AD.

Table SI.2. Important Co-morbidities

Co-morbidity	Prevalence in AD Population (Unless Other Measure Noted)
Depression	AD was associated with double the odds of self-reported clinical depression or clinician-diagnosed depression in adults (OR = 1.99, 95% CI: 1.53 to 2.59) (Davis et al. 2022). The prevalence of depression in patients with AD is reported as follows: Adults • 20.1% (multinational, meta-analysis; Patel et al. 2019) • 21.8% self-reported depression (multinational; Simpson et al. 2016) • 3.0% to 10.1% (EU; Dalgard et al. 2015; Egeberg et al. 2017a) • 17.5% (US; Yu and Silverberg et al. 2015) • 16.1% depressive symptoms of at least 2-weeks duration (Korea; Kim et al. 2015a) • 10.25% self-reported depression (Japan; Arima et al. 2018) Adolescents • 1.3% (South Korea, aged 13 to 18 years; Ahn et al. 2019) • 0.1% (multinational, aged <18 years; Gilaberte et al. 2020)

Co-morbidity	Prevalence in AD Population (Unless Other Measure Noted)
Anxiety	AD was associated with an increased odds of anxiety in adults (OR = 1.40, 95% CI: 1.12 to 1.75) (Davis et al. 2022). The prevalence of anxiety in patients with AD is reported as follows: Adults • 21.8% self-reported anxiety (multinational; Simpson et al. 2016) • 1.2% to 17.6% (EU; Dalgard et al. 2015; Egeberg et al. 2017a) • 42.5% self-reported anxiety (US; Whiteley et al. 2016) • 9.8% male patients with AD (Korea; Kim et al. 2015b) • 3.3% self-reported anxiety (Japan; Arima et al. 2018) Adolescents • 1.3% (South Korea, aged 13-18 years; Ahn et al. 2019) • 0.2% anxiety, neuroses (multinational, aged <18 years; Gilaberte et al. 2020)
Suicidal ideation/behaviours	Adults with AD are more likely to have suicidal ideation than adults without AD (OR = 1.71, 95% CI: 1.43 to 2.03) (Davis et al. 2022). The prevalence of suicidal ideation in adults with AD, unless noted, is as follows: Suicidal ideation • 12.2% (multinational, meta-analysis; Patel et al. 2019) • 15.0% to 21.3% (EU; Dalgard et al. 2015; Dieris-Hirche et al. 2017) • 0.2% (South Korea, aged 13-18 years; Ahn et al. 2019) Suicide attempt • 6.6% (EU; Dieris-Hirche et al. 2017)
Allergic rhinitis	Allergic rhinitis is a recognised common co-morbidity of AD and a component of some diagnostic criteria for AD (Davis et al. 2022). The prevalence of allergic rhinitis in patients with AD is reported as follows: Adults • 51.3% patient-reported (multinational; Simpson et al. 2016) • 21.0% to 25.2% in Poland and Germany, respectively (Sybilski et al. 2015; Radtke et al. 2017) • 30% hay fever (US; Hanifin et al. 2007; Whiteley et al. 2016) • 27.3% to 30.5% (Taiwan; Wu et al. 2014; Cheng et al. 2015) • 36.9% patient-reported (Japan; Arima et al. 2018) Adolescents • 30.7% to 34.5% hay fever (US, aged <18 years; Shaw et al. 2011; Yaghmaie et al. 2013) • 42.9% (South Korea, aged 13-18 years; Ahn et al. 2019) • 7.1% (multinational, aged <18 years; Gilaberte et al. 2020)
Conjunctivitis	Prevalence of conjunctivitis varies greatly, as this is a clinically non-specific event that can have multiple aetiologies. The prevalence of conjunctivitis in patients with AD is reported as follows:

Co-morbidity	Prevalence in AD Population (Unless Other Measure Noted)
	Adults 3.7% based on ICD-10 codes, and up to 18.9% based on treatment with anti-inflammatory topical ophthalmic products (Denmark; Thyssen et al. 2017) 18.75% allergic conjunctivitis; 1.25% keratoconjunctivitis (Malaysia; Gan et al. 2022) 12.7% current conjunctivitis at the time of survey, 66.6% lifetime prevalence (Denmark; Ronnstad et al. 2022) Adolescents 14.3%, allergic conjunctivitis (South Korea, aged 13-18 years; Ahn et al. 2019) 13.4% conjunctivitis (US, aged <18 years; Paller et al. 2022)
Asthma	Adults with AD are 3 times more likely to have asthma compared with general population (Davis et al. 2022). The prevalence of asthma in patients with AD is reported as follows: Adults 24.8% in meta-analysis (Davis et al. 2022) 40.3% patient-reported (multinational; Simpson et al. 2016) 4.0% (Poland; Sybilski et al. 2015) to 17.77% (Germany; Radtke et al. 2017) 22.4% to 33% (US; Hanifin et al. 2007; Whiteley et al. 2016) 2.14% to 30.2% (Asia; Wu et al. 2014; Takaki and Ishii 2013) 12.62% patient-reported (Japan; Arima et al. 2018) Adolescents 22.8% to 25.2% (US, aged <18 years; Shaw et al. 2011; Yaghmaie et al. 2013) 6.3% (South Korea, aged 13-18 years; Ahn et al. 2019) 13.1% (multinational, aged <18 years; Gilaberte et al. 2020)
Food allergy	The odds of having food allergy among adults with AD compared with the general population increases with increasing AD severity. Among those with moderate AD, the RR was reported as 2.40 (95% CI: 1.54 to 3.27) and among those with severe AD, the RR was reported as 8.49 (95% CI: 5.44 to 11.54) (Davis et al. 2022). The prevalence of food allergy in patients with AD is reported as follows: Adults 11% in meta-analysis (Davis et al. 2022) 14.6% self-reported (US; Silverberg et al. 2018) Adolescents 15.1% (US, aged 0-17 years; Yaghmaie et al. 2013)

Co-morbidity	Prevalence in AD Population (Unless Other Measure Noted)
Alopecia areata	Epidemiologic studies have shown an association between AD and AA (Mohan and Silverberg 2015). However, the magnitude of the association is unclear due to diagnostic bias. The prevalence of AA in patients with AD is reported as follows: Adults 0.1% to 0.95% (US; Narla and Silverberg 2019; Andersen et al. 2017) Adolescents 0.04% (US, aged 0-17 years; Narla and Silverberg 2019)
Skin infections	Patients with AD have dramatically increased odds of being colonised with <i>S. aureus</i> than controls on lesion skin (OR = 19.74, 95% CI: 10.88 to 35.81) (Totte et al. 2016). The prevalence of skin infections in patients with AD is reported as follows: <i>S. aureus</i> colonisation 73% to 77.5% (Germany; Thum et al. 2013; Ong and Leung 2016; Clausen et al. 2017) 70% for lesional skin, 39% non-lesional skin, 62% for the nose (multinational, meta-analysis; Totte et al. 2016) 19% bacterial infections (impetiginised eczema, folliculitis, cellulitis) and 3% viral infections (eczema herpeticum, viral warts, molluscum contagiosum) (Singapore; Tay et al. 1999)
Herpes infections	Herpes simplex virus infections are more than twice as common among patients with AD compared with general population controls (Davis et al. 2022). The prevalence of herpes infections in patients with AD is reported as follows: Eczema herpeticum 2% to 3% (Leung 2013; Blauvelt et al. 2017)
Cardiovascular disease	According to a guideline from the American Academy of Dermatology (Davis et al. 2022), there is mounting evidence for a small association between AD and various CV conditions. For stroke, myocardial infarction, and CV death, there may be a severity gradient with uncertain risk for adults with mild AD and potentially increased risk in adults with severe AD (Davis et al. 2022). The incidence rate of various cardiac outcomes in patients with AD is reported as follows: Stroke 0.27 per 100 PY (Denmark; Andersen et al. 2016) (UK; Silverwood et al. 2018) Myocardial infarction 0.20 per 100 PY (Denmark; Andersen et al. 2016) (UK; Silverwood et al. 2018) CV Death 0.29 to 0.44 per 100 PY (Denmark; Andersen et al. 2016) (UK; Silverwood et al. 2018)

Co-morbidity	Prevalence in AD Population (Unless Other Measure Noted)
Skin cancer	Data for skin cancers, including melanoma and non-melanoma skin cancers, are mixed, with some literature suggesting increased risks for adults with AD, and others suggesting no risk (Andersen et al. 2017; Paller et al. 2018). The incidence rate of skin cancer in patients with AD is reported as follows: Melanoma • 0.04 per 100 PY (US; Hedderson et al. 2021) • 0.02 per 100 PY (UK; Arana et al. 2010) • 0.03 per 100 PY (England; Mansfield et al. 2020) Non-melanoma Skin Cancer • 0.48 per 100 PY (US; Hedderson et al. 2021) • 0.88 per 100 PY (UK; Arana et al. 2010) • 0.29 per 100 PY (England; Mansfield et al. 2020)
CTCL/mycosis fungoides	Prevalence of CTCL and mycosis fungoides is not directly available within an AD population. There is a slightly increased risk of lymphoma in adults with AD, with severity of AD as a significant risk factor (Legendre et al. 2015; Paller et al. 2018; Mansfield et al. 2020). For example, the risk of NHL in patients with AD increased with increasing severity versus those without AD (HR = 1.06 for mild AD, HR = 1.24 for moderate AD, HR = 2.08 for severe AD) (Mansfield et al. 2020). • CTCL is a relatively rare subtype of NHL, comprising 2% to 3% of all NHL cases (Phan et al. 2016)

Abbreviations: AA = alopecia areata; AD = atopic dermatitis; CI = confidence interval; CTCL = cutaneous T-cell lymphoma; CV = cardiovascular; ICD-10 = International Statistical Classification of Diseases and Related Health Problems 10th Revision; NHL = non-hodgkin lymphoma; OR = odds ratio; PY = patient-years; RR = relative risk.

Module SII – Non-clinical Part of the Safety Specification

Key safety findings from non-clinical studies and relevance to human usage:

SII.1 Toxicity

Repeat-Dose toxicity

Non-clinical toxicity findings attributed to lebrikizumab and of potential clinical significance were limited to subcutaneous ISRs. Swelling in the area of injection was identified in 1 monkey and did not worsen with repeated dosing.

ISRs were reported with a low frequency (3.1%) in -lebrikizumab treated patients across all AD studies. All events were non-serious and most patients (94.3%) reported events with mild or moderate severity.

Carcinogenicity

Carcinogenicity studies of lebrikizumab have not been conducted. No tumours or precancerous lesions were observed in monkeys that received lebrikizumab for up to 9 months. Among lebrikizumab-treated patients across all AD studies, a total of 13 (0.8%) patients reported 20 events of malignancy, of which 10 events from 5 patients were NMSC. All the NMSC events were non-serious. Malignancies other than non-NMSC reported among lebrikizumab-treated patients across all AD studies were mostly single events with no trend in the type of tumours.

Reproductive or developmental toxicity

No significant effects were observed related to reproductive or developmental toxicity in sexually mature or pregnant monkeys who received lebrikizumab.

SII.2 Safety Pharmacology

No significant cardiovascular, respiratory, or central nervous system findings were observed in monkeys who received lebrikizumab.

SII.3 Other Toxicity-Related Information or Data

Not applicable, as there were no other clinically relevant findings in non-clinical studies.

Module SIII - Clinical Trial Exposure

Clinical trial exposure of lebrikizumab is presented from 8 clinical studies that were designed to evaluate the efficacy and safety of lebrikizumab in patients with AD:

- one Phase 2, randomised open-label Study ARBAN (J2T-DM-KGAH [KGAH])
- 5 multicentre, randomised, double-blind, placebo-controlled studies, which include
 - two Phase 2 Studies TREBLE (J2T-DM-KGAG [KGAG]) and J2T-DM-KGAF (KGAF), and
 - three Phase 3 Studies ADvocate 1 (J2T-DM-KGAB [KGAB]), ADvocate 2 (J2T-DM-KGAC [KGAC]), and ADhere (J2T-DM-KGAD [KGAD])
- one Phase 3 long-term safety Study ADjoin (J2T-DM-KGAA [KGAA]), and
- one Phase 3, open-label, adolescent single arm Study ADore (J2T-DM-KGAE [KGAE]).

Additional clinical studies evaluating lebrikizumab in patients with asthma, COPD, IPF, and RHL have also been conducted. A total of 3317 patients with asthma were exposed to any dose of lebrikizumab in Phase 1 to 3 studies. During early phase studies of lebrikizumab in COPD, RHL, and IPF studies, a total of 429 patients were exposed to any dose of lebrikizumab.

Table SIII.1. Duration of Lebrikizumab Exposure

Atopic Dermatitis		
<i>Atopic Dermatitis All Lebrikizumab Exposure Modified Safety Population^a</i>		
Duration of Exposure (Weeks)	Patients	Patient-Years
>0 to <4	23	0.9
≥4 to <16	130	24.7
≥16 to <24	266	99.2
≥24 to <32	120	65.6
≥32 to <40	183	117.2
≥40 to <52	116	102.3
≥52 to <78	613	749.9
≥78 to <104	210	344.1
≥104	59	133.1
Total	1720	1637.0

Abbreviations: AD = atopic dermatitis; GCP = good clinical practice.

^a This population is comprised of patients who received at least 1 dose of study drug in lebrikizumab AD clinical Studies KGAG, KGAH, KGAF, KGAB, KGAC, KGAD, KGAE, and KGAA (as of the data cutoff 06 June 2022). A total of 36 patients exposed to lebrikizumab from 1 study site participating in Studies KGAA, KGAC, and KGAD are excluded from this analysis set due to GCP non-compliance related to protocol entry criteria.

Time spent within any temporary study drug interruption is included within exposure time. Time after permanent study drug discontinuation is not included within exposure time. Total patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

Table SIII.2. Age Group and Gender

Age Group <i>Atopic Dermatitis All Lebrikizumab Exposure Modified Safety Population^a</i>	Patients		Patient-Years	
	M	F	M	F
<65 years				
≥12 to <18 years	172	200	193.8	219.3
≥18 to <30 years	240	264	204.3	234.5
≥30 to <50 years	236	220	216.5	194.9
≥50 to <65 years	124	141	113.0	145.1
≥65 years				
≥65 to <75 years	55	39	57.8	35.1
≥75 to <85 years	15	9	12.4	6.8
≥85 years	1	4	0.5	2.9
Total	843	877	798.4	838.7

Abbreviations: AD = atopic dermatitis; F = female; GCP = good clinical practice; M = male.

^a This population is comprised of patients who received at least 1 dose of study drug in lebrikizumab AD clinical Studies KGAG, KGAH, KGAF, KGAB, KGAC, KGAD, KGAE, and KGAA (as of the data cutoff 06 June 2022). A total of 36 patients exposed to lebrikizumab from 1 study site participating in Studies KGAA, KGAC, and KGAD are excluded from this analysis set due to GCP non-compliance related to protocol entry criteria.

Time spent within any temporary study drug interruption is included within exposure time. Time after permanent study drug discontinuation is not included within exposure time. Total patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

Table SIII.3. Dose

Dose of Exposure <i>Atopic Dermatitis All Lebrikizumab Exposure Modified Safety Population^a</i>	Patients	Patient-Years
LEB 250 Q4W ^b	245	229.1
LEB 250 Q2W ^c	1367	1301.7
LEB 125 Q4W	152	66.0
Other doses (250 mg single dose + TCS, 125 mg single dose + TCS)	105	40.2
Total (any LEB)	1720	1637.0

Abbreviations: AD = atopic dermatitis; GCP = good clinical practice; LEB = Lebrikizumab; Q2W = every 2 weeks; Q4W = every 4 weeks; TCS = topical corticosteroids.

- ^a This population is comprised of patients who received at least 1 dose of study drug in lebrikizumab AD clinical Studies KGAG, KGAH, KGAF, KGAB, KGAC, KGAD, KGAE, and KGAA (as of the data cutoff 06 June 2022). A total of 36 patients exposed to lebrikizumab from 1 study site participating in Studies KGAA, KGAC, and KGAD are excluded from this analysis set due to GCP non-compliance related to protocol entry criteria.
- ^b Includes all patients who were ever exposed to LEB 250 mg Q4W during the trial.
- ^c Includes all patients who were ever exposed to LEB 250 mg Q2W during the trial.

Time spent within any temporary study drug interruption is included within exposure time. Time after permanent study drug discontinuation is not included within exposure time. Total patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

Table SIII.4. Ethnic Origin

Ethnic Origin <i>Atopic Dermatitis All Lebrikizumab Exposure Modified Safety Population^a</i>	Patients	Patient-years
American Indian or Alaska Native	26	25.3
Asian	311	301.6
Black or African American	232	203.0
Native Hawaiian or other Pacific Islander	9	9.1
White	1079	1039.0
Multiple	40	40.8
Other	17	14.8
Not reported	5	3.1
Unknown	1	0.4
Total	1720	1637.0

Abbreviations: AD = atopic dermatitis; GCP = good clinical practice

^a This population is comprised of patients who received at least 1 dose of study drug in lebrikizumab AD clinical Studies KGAG, KGAH, KGAF, KGAB, KGAC, KGAD, KGAE, and KGAA (as of the data cutoff 06 June 2022). A total of 36 patients exposed to lebrikizumab from 1 study site participating in Studies KGAA, KGAC, and KGAD are excluded from this analysis set due to GCP non-compliance related to protocol entry criteria. Time spent within any temporary study drug interruption is included within exposure time. Time after permanent study drug discontinuation is not included within exposure time. Total patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

No International Database lock was available at the time of this RMP update. Table SIII. 5 and Table SIII. 6 provide updated data with a cut-off date of 16 Nov 2024 based on exposure data from completed clinical trials and the enrolment/randomisation schemes for ongoing trials.

Table SIII. 5. Estimated Cumulative Subject Exposure in Completed and Ongoing Lebrikizumab Clinical Trials as of 16 November 2024

Treatment	Number of Subjects
Lebrikizumab ^a	7724
Placebo	2823
Comparator(s) ^b	129

^a Lebrikizumab includes all subjects allocated to receive lebrikizumab, combined across all doses of lebrikizumab.

^b Comparator(s) include all subjects allocated to a comparator drug, combined across all such drugs.

Notes: Subjects who are allocated to treatment regimens that may include more than 1 of lebrikizumab, placebo, and comparator are counted in each applicable treatment category. For trials that remain blinded to the study team at the time of this report, the number of subjects is estimated based upon the study randomisation scheme.

Source: statsclstr/lillyce/prd/1y3650150/arnov2024/output/shared/tfl/1y3650150_psur_2024_expos1.rtf

Table SIII. 6. Cumulative Subject Exposure to Lebrikizumab by Age Group and Gender: All Completed and Unblinded Ongoing Clinical Trials through 16 November 2024

Age Group	Male (n) (N=3434)	Female (n) (N=3885)	Unknown (n) (N=2)	Total (n) (N=7321)
<12 years	0	0	0	0
≥12 and <18 years	402	378	0	780
≥18 and <65 years	2554	3101	0	5655
≥65 years	478	406	0	884
Unknown	0	0	2	2

Abbreviations: n = number of subjects in the specified category; N = total number of subjects.

Source: statsclstr/lillyce/prd/ly3650150/arnov2024/output/shared/tfl/1y3650150_psur_2024_demog1.rtf

Additional exposure data is also available for the completed clinical trial J2T-DM-KGAA and J2T-AP-KGBQ (M-17923-30). Table SIII. 7 and Table SIII. 8 provide the Exposure by Treatment Group Study KGAA and KGBQ:

Table SIII. 7. Exposure by Treatment Group Study KGAA Main Cohort Modified Safety Population

	LEB 250 mg Q4W (N = 141)	LEB 250 mg Q2W (N = 1012)	Total (N = 1153)
Mean days of exposure (SD)	625.5 (179.3)	579.4 (215.5)	585.0 (211.9)
≥30 days, n (%)	141 (100.0)	1004 (99.2)	1145 (99.3)
≥183 days, n (%)	134 (95.0)	919 (90.8)	1053 (91.3)
≥365 days, n (%)	123 (87.2)	806 (79.6)	929 (80.6)
≥548 days, n(%)	115 (81.6)	723 (71.4)	838 (72.7)
≥730 days, n(%)	12. (8.5)	83 (8.2)	95 (8.2)
Total participant-years^a	241.48	1605.37	1846.84

Abbreviations: LEB = lebrikizumab; n = number of participants in the specified category; N = number of participants in the analysis population; Q2W = every 2 weeks; Q4W = every 4 weeks; SD = standard deviation.

^a Total exposure in participant-years is calculated as sum of duration of exposure in days for all participants in dosing regimen divided by 365.25.

Source: Table KGAA.8.30.

Table SIII. 8. Exposure by Treatment Group Study KGBQ Safety Population

	LEB 250 mg Q2W (N = 220)	Placebo (N = 111)	Total (N = 311)
Mean days of exposure (SD)	349.0 (123.5)	324.9 (131.1)	340.9 (126.4)
≥30 days, n (%)	216 (98.2%)	107 (96.4%)	323 (97.6%)
≥183 days, n (%)	200 (90.9%)	93 (83.8%)	293 (88.5%)
≥365 days, n (%)	32 (14.5%)	12 (10.8%)	44 (13.3%)
≥548 days, n (%)	18 (8.2%)	6 (5.4%)	24 (7.3%)
Total participant-years^a	210.20	98.75	308.94

Abbreviations: LEB = lebrikizumab; n = number of participants in the specified category; N = number of participants in the analysis population; Q2W = every 2 weeks; SD = standard deviation.

^aTotal exposure in participant-years is calculated as sum of duration of exposure in days for all participants in dosing regimen divided by 365.25

Module SIV - Populations Not Studied in Clinical Trials

SIV.1 Exclusion Criteria in Pivotal Clinical Studies within the Development Programme

Criterion: Patients younger than 12 years and adolescent patients (12 years and older) weighing less than 40 kg

Reason for exclusion: The safety and efficacy of lebrikizumab have not been established for

- patients younger than 12 years, and
- adolescent patients (12 years and older) weighing less than 40 kg.

To establish the efficacy and safety of lebrikizumab, Phase 3 clinical trials were conducted first in adults and adolescents (12 years and older who weigh at least 40 kg). Therefore, the populations of patients younger than 12 years of age and 12 years of age and older weighing less than 40 kg are under investigation.

Is it considered to be included as missing information?: No

Rationale: The prescribing information will clearly state that the safety and efficacy of lebrikizumab in children below the age of 12 years and adolescents aged 12 to 17 years weighing less than 40 kg have not yet been established. Additionally, approved, alternative therapeutic options are available for the treatment of AD in these paediatric or adolescent patients. It was agreed with regulatory agencies of the US and the EU to start studies in other paediatric populations once a positive risk-benefit in adults and adolescents aged at least 12 years has been established. Additional Phase 3 studies in the paediatric and adolescent populations are currently ongoing.

Criterion: Pregnant or breastfeeding women

Reason for exclusion: This is a standard exclusion criterion in clinical development. Although no significant effects were observed related to reproductive or developmental toxicity in sexually mature or pregnant monkeys who received lebrikizumab, there are insufficient human data to establish the safety of lebrikizumab during pregnancy and lactation.

Is it considered to be included as missing information?: Yes

Rationale: Not applicable.

SIV.2 Limitations to Detect Adverse Reactions in Clinical Trial Development Programmes

The clinical development programme is unlikely to detect certain types of adverse reactions, such as rare adverse reactions, adverse reactions with a long latency, or those caused by prolonged or cumulative exposure.

SIV.3 Limitations in Respect to Populations Typically Under-Represented in Clinical Trial Development Programmes

Table SIV.1. Exposure of Special Populations Included or Not in Clinical Trial Development Programmes

Type of special population	Exposure
Pregnant women	Pregnancy was an exclusion criterion in the clinical development programme.
Breastfeeding women	Not included in the clinical development programme.
Patients with relevant co-morbidities: Patients with hepatic impairment Patients with cardiovascular impairment Immunocompromised patients	Lebrikizumab has not been specifically studied in patients with these co-morbidities.
Patients with uncontrolled severe asthma Patients with prior history of anaphylaxis	Severe and uncontrolled asthma and prior history of anaphylaxis were exclusion criteria in the AD clinical development programme.
Patients using live vaccine	Patients who received live vaccines were excluded from trials in the AD clinical development programme.
Patients with a disease severity different from inclusion criteria in clinical trials	The clinical development programme included patients with moderate to severe AD. Patients with mild disease were not specifically studied.
Patients with renal impairment	Lebrikizumab has not been specifically studied in patients with renal impairment. In the AD clinical development programme, 33 (2.4%) patients with moderate decrease in eGFR (≥ 30 and < 60 mL/min/1.7m ²) and 2 (0.1%) patients with severe decrease in eGFR (≥ 15 and < 30 mL/min/1.7m ²) were exposed to lebrikizumab. No patients with end stage renal disease (eGFR < 15 mL/min/1.7m ²) were included in AD clinical development programme.
Population with relevant different ethnic origin	Per data presented in Table SIII. , the distribution of patients of different ethnic origins is generally reflective of the anticipated target population.
Subpopulations carrying relevant genetic polymorphisms	Not applicable. Patient-level genetic polymorphisms were not specifically studied in the clinical development programme.

Abbreviations: AD = atopic dermatitis; eGFR = estimated glomerular filtration rate.

Module SV - Post-Authorisation Experience

SV.1 Post-Authorisation Exposure

SV.1.1 Method Used to Calculate Exposure

Lebrikizumab's posology includes 2 loading doses of 500 mg for 2 weeks and subsequent 14 weeks of Q2W dosing of 250mg, totaling a 16-week induction period. This is followed by a Q4W maintenance dosing injection schedule. Some patients may stay on Q2W dosing beyond 16 weeks until they reach adequate clinical response before moving to Q4W maintenance. It is expected that during the initial months of the drug being available in each geography, most of the patients could be under a Q2W schedule. Later, with time, more patients are expected to be well controlled in a Q4W schedule.

For patient exposure estimates purposes at this time, the estimated daily dose was defined based on a 250 mg Q4W dose schedule, assuming all the drugs sold are reaching patients. Therefore, it needs to be recognized that any estimations at this early stage of market availability are likely to reflect sold drug not yet available for purchase and will carry a degree of overestimation.

Estimated Patient-Years (PY) of exposure for lebrikizumab are calculated dividing the total number of milligrams sold by the estimated daily dose (EDD) to obtain total days of therapy. The total days of therapy are then divided by 365 to obtain the estimated PY of exposure to lebrikizumab. Estimates for EDD were determined based on the established maintenance dose of 250 mg every 4 weeks (approximately 8.9 mg per day).

SV.1.2 Exposure

Cumulatively as of 31 August 2025, 111 783 300 mg of lebrikizumab were sold worldwide, leading to an estimate of approximately 34 300 PY of exposure worldwide. Table SV.1 provides a cumulative summary of estimated patient-years of exposure for lebrikizumab.

Table SV.1. Cumulative Geographical Summary Estimated Patient Exposure for lebrikizumab through 31 August 2025

Region	Sales Ex-factory (milligrams)	Patient-years of exposure ^a
Europe	41 827 750	12 800
Japan		
Other countries	6 999 800	2100
United States		
Global totals	111 783 300	34 300

^aTotals may not sum due to independent rounding.

Module SVI – Additional EU requirements for the Safety Specification

SVI.1 - Potential for Misuse for Illegal Purposes

The potential for misuse of lebrikizumab for illegal purposes is not considered to be a significant risk, particularly in the absence of associated euphoric or other central nervous system effects associated with addictive behaviour. This class is not known to produce dependence syndromes. In clinical studies of lebrikizumab to date, there have been no findings indicating that lebrikizumab causes physical or mental dependency.

Module SVII - Identified and Potential Risks

SVII.1 Identification of Safety Concerns in the Initial RMP Submission

SVII.1.1 Risks Not Considered Important for Inclusion in the List of Safety Concerns in the RMP

Risks with minimal clinical impact on patients (in relation to the severity of the indication treated):

- None

Adverse reactions with clinical consequences, even serious, but occurring with a low frequency and considered to be acceptable in relation to the severity of the indication treated:

- None

Known risks that require no further characterisation and are followed up via routine pharmacovigilance namely through signal detection and adverse reaction reporting, and for which the risk minimisation messages in the product information are adhered by prescribers:

- Conjunctivitis: For the AD Induction Period Placebo-Controlled Integrated Analysis Set (AD ALL PC Weeks 0 to 16), conjunctivitis was reported for 67 (8.6%) patients receiving lebrikizumab 250 mg Q2W compared with 10 (2.5%) patients receiving placebo. All events of conjunctivitis were non-serious and mild or moderate in severity. A total of 3 (0.4%) patients receiving lebrikizumab 250 mg Q2W discontinued the study treatment due to conjunctivitis.

For AD All Lebrikizumab Exposure Analysis Set (AD ALL LEB), conjunctivitis events were reported in 10.6% patients treated with lebrikizumab. Events were non-serious and mostly mild-to-moderate in intensity (97.4%). A total of 17 (1.0%) patients discontinued the study treatment due to conjunctivitis.

- Keratitis: For AD ALL PC Weeks 0-16, keratitis was reported for 5 (0.6%) patients receiving lebrikizumab 250 mg Q2W compared to 1 (0.2%) patient receiving placebo during the Induction Period. All events of keratitis were non-serious and moderate in severity. A total of 2 (0.3%) patients receiving lebrikizumab 250 mg Q2W discontinued the study treatment due to keratitis.

For AD ALL LEB, keratitis events were reported in 9 (0.5%) patients treated with lebrikizumab. A total of 3 (0.2%) patients discontinued the study treatment due to keratitis. Events were non-serious and mainly mild or moderate in severity (92.8%).

- ISRs: For AD ALL PC Weeks 0-16, ISRs were reported for 20 (2.6%) patients receiving lebrikizumab 250 mg Q2W compared with 6 (1.5%) patients receiving placebo. All ISR events were non-serious. Except for 1 patient receiving lebrikizumab, all the ISR events were mild or moderate in severity. A total of 2 (0.3%) patients discontinued the study treatment due to ISR.

For AD ALL LEB, ISR events were reported in 3.1% patients treated with lebrikizumab. All events were non-serious, and most patients (94.3%) reported

events with mild or moderate severity. A total of 5 (0.3%) patients discontinued the study treatment due to ISR.

- **Eosinophilia:** For AD ALL PC Weeks 0 to 16, blood eosinophil increased to severe category (more than 5000 cells per microlitre) for 3 (0.4%) patients receiving lebrikizumab 250 mg Q2W compared to 0 patients receiving placebo.

For AD ALL LEB, blood eosinophil increased to severe category (more than 5000 per microlitre) for 8 (0.5%) patients.

In general, the eosinophilia was transient, did not result in discontinuation and was not associated with adverse events.

- **Herpes zoster:** For AD ALL PC Weeks 0 to 16, herpes zoster was reported for 5 (0.6%) patients receiving lebrikizumab 250 mg Q2W compared with 0 patients receiving placebo. All events of herpes zoster were non-serious, mild or moderate in severity and none led to discontinuation.

For AD ALL LEB, herpes zoster events were reported in 14 (0.8%) patients treated with lebrikizumab. No patients discontinued the study treatment due to herpes zoster. All events were non-serious and mild or moderate in severity.

Known risks that do not impact the risk-benefit profile:

- None

Other reasons for considering the risks not important:

- None

SVII.1.2 Risks Considered Important for Inclusion in the List of Safety Concerns in the RMP

Important Identified Risk: None

Important Potential Risk: None

Missing Information 1: Use in pregnant and breastfeeding women

Risk-benefit impact:

The current data are too limited to draw conclusions about the effect of lebrikizumab exposure during pregnancy and lactation in humans.

No significant effects were observed related to reproductive or developmental toxicity in sexually mature or pregnant monkeys who received lebrikizumab. There were no effects on reproductive organs or fertility parameters assessed in sexually mature females (menstrual cycling, reproductive hormones) or males (semen or sperm analysis). Administration of lebrikizumab to pregnant monkeys throughout organogenesis in an embryo-foetal development study and throughout organogenesis through parturition in a pre- and postnatal development study identified no embryo-

foetal toxicity or adverse effects on the growth, development, or immune system function of offspring.

Pregnant women were excluded from entering lebrikizumab clinical studies. Women of child-bearing potential were included after agreeing to comply with protocol-specified pregnancy testing and contraceptive requirements, and male participants were not required to use contraception. Pregnancies that occurred in female clinical trial participants was a criterion for permanent discontinuation of lebrikizumab in all studies, and pregnant participants and partner pregnancies who consented are followed up until pregnancy completion.

Cumulatively, there have been 1421 females of reproductive potential enrolled in lebrikizumab clinical trials for AD and asthma. These patients are defined by the Center for Disease Control and Prevention as females aged between 15 to 44 years.

Across all indications, there are limited safety data on the use of lebrikizumab in pregnant women.

As of 06 June 2022, there have been 20 pregnancies from maternal exposure and 5 from paternal exposure reported during the lebrikizumab clinical development programme. There has been no case of exposure to lebrikizumab during lactation.

Although the risk of lebrikizumab to pregnant women with AD is not expected to be different, lebrikizumab will be used among women of childbearing age and there is currently insufficient information to draw conclusions about the safety of exposure during pregnancy. As such, use during pregnancy is considered missing information. An observational database study will be conducted post-approval as a part of the pharmacovigilance plan because of the limited data on pregnancy outcomes. The objectives of the study are 2-fold:

- to estimate occurrence of pregnancy and infant outcomes among women exposed to lebrikizumab in pregnancy,
- if the sample size permits, to evaluate the relative risk of the adverse pregnancy and infant outcomes among women with AD exposed to lebrikizumab in pregnancy compared to women with AD unexposed to lebrikizumab in pregnancy..

Should emerging experience of such use in pregnancy reveal clinically significant adverse outcomes to the mother, foetus, baby, or all, this could have an impact on the risk-benefit of lebrikizumab use in female patients with AD.

Missing Information 2: Long-term safety of lebrikizumab.

Risk-benefit impact:

Moderate-to-severe AD is a complex and chronic disease requiring treatment for long periods of time. The maximum treatment exposure duration is 939 days in the AD clinical development programme. Additional clinical studies to evaluate lebrikizumab in patients with asthma, COPD, IPF, and RHL have also been conducted. There has been no patient exposure outside of the clinical

development program. As such, long-term safety of lebrikizumab is considered missing information.

The ongoing Study KGAA evaluates the long-term safety and efficacy of lebrikizumab in patients with moderate-to-severe AD and is a part of the pharmacovigilance plan for further characterising long-term safety.

Additionally, patients enrolled at centres in Germany and Poland who completed Study KGAA are eligible to participate in the ongoing, long-term safety and efficacy study M-17923-32, which will provide up to 2 additional years of treatment. Cumulative data from the parent study plus studies KGAA and M-17293-32 will enable collection of lebrikizumab safety data for up to a total of 5 years of continuous treatment.

If the data demonstrate that long-term lebrikizumab use is associated with adverse outcomes or morbidity, this could have an impact on the risk-benefit of lebrikizumab use in the context of a chronic and relapsing disease, which when left untreated or uncontrolled can have a significant impact on sleep, mood, anxiety, and social function.

SVII.2 New Safety Concerns and Reclassification with a Submission of an Updated RMP

Not applicable

SVII.3 Details of Important Identified Risks, Important Potential Risks, and Missing Information

SVII.3.1 Presentation of Important Identified Risks and Important Potential Risks

Important Identified Risk:

None

Important Potential Risk:

None

SVII.3.2 Presentation of the Missing Information

Missing Information: Use in pregnant and breastfeeding women.

Evidence source:

Cumulatively as of 06 June 2022, there were 25 pregnancies across all lebrikizumab indications. Of these, 10 were reported in the AD clinical development programme and 15 occurred during the asthma interventional studies.

A total of 20 women became pregnant during their lebrikizumab study participation, and partners of 5 male participants became pregnant during the male participant's lebrikizumab study participation.

Table SVII.1, within the 25 pregnancies, 19 cases reported pregnancy outcomes, and 6 cases were still in utero or lost to follow-up.

Table SVII.1. Neonate Birth Type in Lebrikizumab Clinical Trials by Indication

Neonate Birth Type	Atopic Dermatitis Clinical Trials ^a	Asthma Clinical Trials ^b	All Lebrikizumab Clinical Trials
Elective termination	4	2	6
Full-term	3	4	7
Spontaneous abortion	0	6	6
In utero ^c	3	3	6
Total	10	15	25

^a Includes pregnancies reported in lebrikizumab atopic dermatitis clinical Studies KGAA, KGAB, KGAC, KGAF, and KGAL (as of the data cutoff 06 June 2022).

^b Includes pregnancies reported in lebrikizumab asthma clinical Studies KGAN, KGAO, KGAP, KGAS, and KGAT (as of the data cutoff 06 June 2022).

^c Some cases reported as in utero have been lost to follow-up.

Definitions: Elective termination = a pregnancy that was electively terminated; Full-term = an infant born between 37 and 42 weeks of gestation; In utero = in the uterus, unborn; Spontaneous abortion = failure of embryonic development and expulsion of all or any part of the product of conception before 20 weeks gestation or expulsion of a foetus weighing less than 500 grams.

Seven (28.0%) pregnancies were reported with neonatal outcomes, all of which were full-term ([Table SVII.1](#)). For the 7 pregnancies followed up to delivery across the lebrikizumab clinical development programme, no neonatal congenital anomalies were reported. Perinatal complications were reported in 2 neonates, 1 developed neonatal jaundice, and 1 had foetal growth restriction and hypoglycaemia.

Trimester of exposure was reported for 19 (76.0%) pregnancies. In 17 of these pregnancies, exposure occurred in the first trimester of gestation. The 2 cases who reported exposure during all trimesters had full-term birth with normal neonate outcome.

Although the mechanism of action, non-clinical data, and clinical trial data did not indicate that the safety profile of lebrikizumab is expected to be different in pregnant and lactating women, there are insufficient data to establish the safety of lebrikizumab during pregnancy and lactation in humans.

Population in need of further characterisation:

Pregnant women with moderate-to-severe AD.

Anticipated risk/consequence of the missing information:

The safety profile of lebrikizumab use in pregnant women with moderate--to--severe AD is unknown.

Missing Information: Long-term safety of lebrikizumab

Evidence source:

The long-term safety of lebrikizumab beyond 52 weeks of treatment duration has not been established through the AD clinical programme. As AD is a chronic and relapsing condition, the long-term use of lebrikizumab may occur in clinical practice. There remains a need to obtain long-term safety data. After approval, the study KGAA evaluated the long-term safety lebrikizumab in patients with moderate-to-severe AD for up to 3 years.

Population in need of further characterisation:

Patients with moderate-to-severe AD receiving long-term treatment with lebrikizumab beyond three years.

Anticipated risk/consequence of the missing information:

It could be anticipated that with long-term use, adverse events that are infrequent or have a longer latency period could occur.

SVII.2 New Safety Concerns and Reclassification with a Submission of an Updated RMP

Not applicable

Module SVIII - Summary of the Safety Concerns

Table SVIII.1. Summary of Safety Concerns

Summary of safety concerns	
Important identified risks	None
Important potential risks	None
Missing information	Use in pregnant and breastfeeding women Long-term safety of lebrikizumab

Part III: Pharmacovigilance Plan (Including Post-Authorisation Safety Studies)

III.1 Routine Pharmacovigilance Activities

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:

None proposed.

III.2 Additional Pharmacovigilance Activities

Study Short Name and Title: Observational Database Study of Pregnancy and Infant Outcomes among Women Exposed to Lebrikizumab During Pregnancy (Study J2T-MC-B003)

Rationale and Study Objectives:

Pregnant women were excluded from lebrikizumab clinical trials, and if a pregnancy did occur during the trial, the patient permanently discontinued study drug. Developmental toxicity studies in pregnant cynomolgus monkeys revealed no evidence of harm to the foetus or infant.

However, the indicated population for lebrikizumab includes women of childbearing age. Given the limited information available on pregnancy outcomes, an observational study is warranted in the post-marketing setting.

This study aims to evaluate the safety of lebrikizumab in pregnant women and their infants. The safety outcomes of interest include pregnancy outcomes (recognized spontaneous abortion, stillbirth, preterm birth) and infant outcomes (small for gestational age, major congenital malformations). There are 2 study objectives:

1. To estimate the occurrence of adverse pregnancy and infant outcomes of interest among the following:
 - a. women (and infants linked to these women) with moderate to severe AD who are exposed to lebrikizumab in pregnancy [Lebrikizumab AD Cohort]
 - b. women (and infants linked to these women) with AD who are exposed during pregnancy to systemic therapies (specifically, oral JAKi, cyclosporine, or azathioprine) [Systemic Therapy AD Cohort]
 - c. women (and infants linked to these women) with AD who are unexposed during pregnancy to these systemic therapies [Unexposed AD Cohort].
2. If the sample size permits, to evaluate the relative risk of the adverse pregnancy and infant outcomes among women with moderate to severe AD (and infants linked to these women) who are exposed to lebrikizumab in pregnancy compared to
 - a. The Systemic Therapy AD Cohort
 - b. The Unexposed AD Cohort

Study Design:

Observational cohort study using secondary data from a US-based administrative claims database where de-identified records of mothers and their offspring can be linked with high accuracy.

Study Population:

There will be 3 cohorts of interest in the descriptive and comparative analysis: 1) women with a diagnosis of AD exposed to lebrikizumab during pregnancy ('lebrikizumab AD cohort'), 2) an active comparator cohort of women with AD who are exposed during pregnancy to systemic therapies indicative of moderate to severe AD ('systemic therapy AD cohort'), and 3) a secondary comparator cohort of women with AD who are unexposed during pregnancy to systemic therapies ('unexposed AD cohort').

Milestones:

Milestone	Planned Date
Submission of protocol	Within 6 months of the European Commission decision anticipated 31 May 2024
Start of data collection/extraction	30 Sep 2026 (e.g. Within 2 years of regulatory approval in the US)
Study Progress Reports	Included in PSUR [§]
End of data collection/extraction	30 September 2032
Final report of study results	Estimated 30 September 2033

[§] After start of data collection/extraction

Study Short Name and Title: Long-term safety and efficacy of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis (M-17923-32).

Rationale and Study Objectives:

The objective of Study M-17923-32 is to examine the long-term safety and efficacy of lebrikizumab in adults and adolescents with moderate-to-severe AD. Patients enrolled in Study KGAA at centres in Germany and Poland who completed the study are eligible to participate in M-17923-32. Cumulative data from the parent study plus studies KGAA and M-17293-32 will enable collection of lebrikizumab safety data for a total of up to 5 years of continuous treatment.

The primary endpoint of the study is the proportion of patients discontinued from study treatment due to treatment-emergent AEs through the last study visit.

Safety will also be assessed based on the incidence of AEs, including serious AEs and AEs of special interest.

Study Design:

Study M-17923-32 is an open-label study to assess the long-term safety and efficacy of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.

All patients receive open-label treatment with lebrikizumab 250 mg administered every 4 weeks (Q4W), regardless of their treatment regimen in Study KGAA. If patient's response is less than a 50% reduction from baseline in the Eczema Area and Severity Index (EASI50), lebrikizumab dosing frequency may be increased to Q2W at any time during the course of the study; thereafter, lebrikizumab Q4W dosing may be resumed at the Investigator's discretion.

Study Population:

Adult and adolescent (12 to <18 years and weighing ≥ 40 kg) patients with moderate-to-severe AD. The study is open to patients enrolled in Study KGAA at centres in Germany and Poland who completed the study.

III.3 Summary Table of Additional Pharmacovigilance Activities

Table Part III.1. Ongoing and Planned Additional Pharmacovigilance Activities

Study Status	Summary of objectives	Safety concerns addressed	Milestones	Estimated Due Dates
Category 3 - Required additional pharmacovigilance activities				
Post-marketing observational study of pregnancy and infant outcomes among women exposed to lebrikizumab during pregnancy in US-based Administrative Claims Data (J2T-MC-B003) <i>Planned</i>	Objectives include: - to estimate occurrence of pregnancy and infant outcomes among women (and infants linked to these women) from 3 cohorts: 1) those with moderate to severe AD exposed to lebrikizumab in pregnancy, 2) those in a systemic therapy AD cohort, and 3) those in an unexposed AD cohort (see Part III.2 for details of cohorts). - If the sample size permits, to evaluate the relative risk of the adverse pregnancy and infant outcomes among women with moderate to severe AD exposed to lebrikizumab in pregnancy compared to women with AD in each of the comparator cohorts (ie. The systemic therapy AD cohort and the unexposed AD cohort).	<i>Missing information:</i> Use in pregnant women	<i>Protocol</i> <i>Final Study</i> <i>Report</i>	<i>Within 6 months of EC decision, anticipated 31 May 2024</i> <i>30 September 2033</i>

Part IV: Plans for Post-Authorisation Efficacy Studies

Not applicable

Part V: Risk Minimisation Measures (Including Evaluation of the Effectiveness of Risk Minimisation Activities)

Risk Minimisation Plan

V.1 Routine Risk Minimisation Measures

Table Part V.1. Description of Routine Risk Minimisation Measures by Safety Concern

Safety Concern	Routine Risk Minimisation Activities
Use in pregnant and breastfeeding women	Routine risk communication: • SmPC Section 4.6 • PL Section 2, Pregnancy, breast-feeding and fertility Routine risk minimisation activities recommending specific clinical measures to address the risk: • SmPC Section 4.6 recommends avoiding the use of lebrikizumab in pregnancy. The use during lactation should be evaluated taking into account the potential benefit-risk. • PL Section 2, Pregnancy, breast-feeding and fertility recommends that it is preferable to avoid the use of Ebglyss in pregnancy and lactation unless your doctor advises to use it. Pack size: Not applicable Legal status: Not applicable
Long-term safety of lebrikizumab	Routine risk communication: None Routine risk minimisation activities recommending specific clinical measures to address the risk: None Pack size: Not applicable Legal status: Available by prescription only

Abbreviations: SmPC = Summary of product characteristics, PL = Package leaflet

V.2 Additional Risk Minimisation Measures

Routine risk minimisation activities as described in Part [V.1](#) are sufficient to manage the safety concerns of the medicinal product.

V.3 Summary of Risk Minimisation Measures

Table Part V.3. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

Safety Concern	Risk Minimisation Measures	Pharmacovigilance Activities
Use in pregnant and breastfeeding women	Routine risk minimisation measures: SmPC Section 4.6 PL Section 2 Additional risk minimisation measures: None proposed	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None proposed. Additional pharmacovigilance activities (Pregnant woman): Observational database study of pregnancy and infant outcomes among women exposed to lebrikizumab during pregnancy (J2T-MC-B003)
Long-term safety of lebrikizumab	Routine risk minimisation: None Additional risk minimisation measures: None proposed	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None proposed Additional pharmacovigilance activities: Long-term safety and efficacy of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis (M-17923-32)

Abbreviations: SmPC = Summary of product characteristics, PL = Package leaflet

Part VI: Summary of the risk management plan for Ebglyss (Lebrikizumab)

This is a summary of the risk management plan (RMP) for Ebglyss. The RMP details important risks of Ebglyss, how these risks can be minimised, and how more information will be obtained about Ebglyss 's risks and uncertainties (missing information).

Ebglyss summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Ebglyss should be used.

This summary of the RMP for Ebglyss should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all of which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Ebglyss's RMP.

I. The medicine and what it is used for

Ebglyss is authorised for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg who are candidates for systemic therapy (see SmPC for the full indication). It contains lebrikizumab as the active substance and it is given by subcutaneous injection.

Further information about the evaluation of Ebglyss's benefits can be found in Ebglyss's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage <[link to the EPAR summary landing page](#)>.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Ebglyss, together with measures to minimise such risks and the proposed studies for learning more about Ebglyss 's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly.
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Ebglyss is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Ebglyss are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Ebglyss. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	Use in pregnant and breastfeeding women Long-term safety of lebrikizumab

II.B Summary of important risks

Missing information: Use in pregnant and breastfeeding women	
Risk minimisation measures	Routine risk minimisation measures: SmPC Section 4.6 recommends avoiding the use of lebrikizumab in pregnancy. The use during lactation should be evaluated taking into account the potential benefit-risk.

	PL Section 2, Pregnancy, breast-feeding and fertility recommends that it is preferable to avoid the use of Ebglyss in pregnancy and lactation unless your doctor advises to use it. Additional risk minimisation measures: None
Additional pharmacovigilance activities	Additional pharmacovigilance activities (Pregnant Women): Observational database study of pregnancy and infant outcomes among women exposed to lebrikizumab during pregnancy See section II.C of this summary for an overview of the post-authorisation development plan.

Missing information: Long-term safety of lebrikizumab	
Risk minimisation measures	Routine risk minimisation measures: None Additional risk minimisation measures: None
Additional pharmacovigilance activities	Additional pharmacovigilance activities: Long-term safety and efficacy of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis (M-17923-32) See section II.C of this summary for an overview of the post-authorisation development plan.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Ebglyss.

II.C.2 Other studies in post-authorisation development plan

Study Short Name: Observational Database Study of Pregnancy and Infant Outcomes Among Women Exposed to Lebrikizumab During Pregnancy (J2T-MC-B003)

Purpose of the study:

To estimate the occurrence of certain adverse pregnancy and infant outcomes among women exposed to lebrikizumab in pregnancy. If the sample size permits, the study aims to estimate the relative risk of the adverse pregnancy and infant outcomes among women with AD exposed to lebrikizumab in pregnancy compared to women with AD unexposed to lebrikizumab in pregnancy.

Study Short Name: Long-term safety and efficacy of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis (M-17923-32)

Purpose of the study:

To evaluate the long-term safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis for up to 2 additional years.

Part VII: Annexes

Annex	Page
[REDACTED]	
[REDACTED]	
[REDACTED]	
Annex 4. Specific adverse drug reaction follow-up forms	55
[REDACTED]	
Annex 6. Details of Proposed Additional Risk Minimisation Activities (if applicable)	57
[REDACTED]	
[REDACTED]	

[REDACTED]

[REDACTED]

[illegible]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED] [REDACTED] [REDACTED]
	[REDACTED] [REDACTED] [REDACTED]		
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	• [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	[REDACTED] [REDACTED] [REDACTED]	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED]			

[REDACTED]

[REDACTED]	[REDACTED] [REDACTED]	[REDACTED]	[REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	[REDACTED] [REDACTED]	[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Annex 4. Specific adverse drug reaction follow-up forms

None

Annex 6. Details of Proposed Additional Risk Minimisation Activities (if applicable)

Not applicable

[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

RMP Ebglyss 250 mg solution for injection (Lebrikizumab)
Version: 1.3
Almirall, S.A.

RMP Ebglyss 250 mg solution for injection (Lebrikizumab)
Version: 1.3
Almirall, S.A.

RMP Ebglyss 250 mg solution for injection (Lebrikizumab)
Version: 1.3
Almirall, S.A.

RMP Ebglyss 250 mg solution for injection (Lebrikizumab)
Version: 1.3
Almirall, S.A.

RMP Ebglyss 250 mg solution for injection (Lebrikizumab)
Version: 1.3
Almirall, S.A.

[REDACTED]

[REDACTED]		
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]

RMP_



ELECTRONIC SIGNATURES

Signed by	Meaning of Signature	Server Date (dd-MMM-yyyy HH:mm 'GMT'Z)
Delia Cristiana Canulescu		

eDMS R&D Object_ID:

